Corvus Pharmaceuticals, Inc.
CRVS
$14.08
-$1.37-8.87%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 2.28M | 2.12M | 2.39M | 2.47M | 2.13M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 12.22M | 10.57M | 10.26M | 9.92M | 8.11M |
| Operating Income | -12.22M | -10.57M | -10.26M | -9.92M | -8.11M |
| Income Before Tax | -12.32M | -10.16M | -8.00M | 15.19M | -12.11M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -12.32M | -10.16M | -8.00M | 15.19M | -12.11M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -12.32M | -10.16M | -8.00M | 15.19M | -12.11M |
| EBIT | -12.22M | -10.57M | -10.26M | -9.92M | -8.11M |
| EBITDA | -12.19M | -10.54M | -10.23M | -9.90M | -8.09M |
| EPS Basic | -0.15 | -0.12 | -0.10 | 0.21 | -0.18 |
| Normalized Basic EPS | -0.09 | -0.08 | -0.06 | 0.13 | -0.11 |
| EPS Diluted | -0.15 | -0.12 | -0.10 | -0.13 | -0.18 |
| Normalized Diluted EPS | -0.09 | -0.08 | -0.06 | 0.13 | -0.11 |
| Average Basic Shares Outstanding | 83.00M | 82.84M | 77.77M | 72.13M | 68.35M |
| Average Diluted Shares Outstanding | 83.00M | 82.84M | 77.77M | 75.15M | 68.35M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |